167 related articles for article (PubMed ID: 29589309)
1. Stool DNA Integrity Method for Colorectal Cancer Detection.
Rengucci C; De Maio G; Menghi M; Calistri D
Methods Mol Biol; 2018; 1765():193-202. PubMed ID: 29589309
[TBL] [Abstract][Full Text] [Related]
2. RT-qPCR for Fecal Mature MicroRNA Quantification and Validation.
Ahmed FE; Ahmed NC; Gouda MM; Vos PW; Bonnerup C
Methods Mol Biol; 2018; 1765():203-215. PubMed ID: 29589310
[TBL] [Abstract][Full Text] [Related]
3. A Stool Multitarget mRNA Assay for the Detection of Colorectal Neoplasms.
Herring E; Kanaoka S; Tremblay E; Beaulieu JF
Methods Mol Biol; 2018; 1765():217-227. PubMed ID: 29589311
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection.
Rengucci C; De Maio G; Menghi M; Benzi F; Calistri D
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32568232
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
6. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.
Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A
J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358
[TBL] [Abstract][Full Text] [Related]
7. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
[TBL] [Abstract][Full Text] [Related]
8. Performance improvements of stool-based screening tests.
van Dam L; Kuipers EJ; van Leerdam ME
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
[TBL] [Abstract][Full Text] [Related]
9. Improved stool DNA integrity method for early colorectal cancer diagnosis.
Rengucci C; De Maio G; Menghi M; Scarpi E; Guglielmo S; Fusaroli P; Caletti G; Saragoni L; Casadei Gardini A; Zoli W; Falcini F; Amadori D; Calistri D
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2553-60. PubMed ID: 25128402
[TBL] [Abstract][Full Text] [Related]
10. Use of integrin alpha 6 transcripts in a stool mRNA assay for the detection of colorectal cancers at curable stages.
Beaulieu JF; Herring E; Kanaoka S; Tremblay É
Oncotarget; 2016 Mar; 7(12):14684-92. PubMed ID: 26895101
[TBL] [Abstract][Full Text] [Related]
11. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.
Calistri D; Rengucci C; Casadei Gardini A; Frassineti GL; Scarpi E; Zoli W; Falcini F; Silvestrini R; Amadori D
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2647-54. PubMed ID: 20929882
[TBL] [Abstract][Full Text] [Related]
12. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
[TBL] [Abstract][Full Text] [Related]
13. Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection.
Pickhardt PJ
Abdom Radiol (NY); 2016 Aug; 41(8):1441-4. PubMed ID: 27259335
[TBL] [Abstract][Full Text] [Related]
14. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China.
Zhang J; Yang S; Xie Y; Chen X; Zhao Y; He D; Li J
Cancer Epidemiol; 2012 Feb; 36(1):73-7. PubMed ID: 21621497
[TBL] [Abstract][Full Text] [Related]
15. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer.
Bechtold ML; Ashraf I; Nguyen DL
South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809
[TBL] [Abstract][Full Text] [Related]
16. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model.
Baxter NT; Koumpouras CC; Rogers MA; Ruffin MT; Schloss PD
Microbiome; 2016 Nov; 4(1):59. PubMed ID: 27842559
[TBL] [Abstract][Full Text] [Related]
17. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
18. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
[TBL] [Abstract][Full Text] [Related]
19. Fecal occult blood testing.
Sanford KW; McPherson RA
Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
[TBL] [Abstract][Full Text] [Related]
20. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S
Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
